Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Imatinib, an inhibitor of the mutant tyrosine kinase that causes chronic myeloid leukemia (CML), is effective in patients with chronic-phase CML who have no response to the standard treatment, interferon alfa. In this study of 1106 patients with previously untreated chronic-phase CML, imatinib was s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	NEW ENGLAND JOURNAL OF MEDICINE 2003-03, Vol.348 (11), p.994-1004
Hauptverfasser:	O'Brien, Stephen G, Guilhot, François, Larson, Richard A, Gathmann, Insa, Baccarani, Michele, Cervantes, Francisco, Cornelissen, Jan J, Fischer, Thomas, Hochhaus, Andreas, Hughes, Timothy, Lechner, Klaus, Nielsen, Johan L, Rousselot, Philippe, Reiffers, Josy, Saglio, Giuseppe, Shepherd, John, Simonsson, Bengt, Gratwohl, Alois, Goldman, John M, Kantarjian, Hagop, Taylor, Kerry, Verhoef, Gregor, Bolton, Ann E, Capdeville, Renaud, Druker, Brian J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzamides Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Clinical trials Cytarabine - administration & dosage Disease Progression Drug therapy Female Humans Imatinib Mesylate Interferon-alpha - administration & dosage Leukemia Leukemia, Myeloid, Chronic-Phase - drug therapy Leukemia, Myeloid, Chronic-Phase - mortality Male Medical sciences Middle Aged Pharmacology. Drug treatments Piperazines - therapeutic use Prospective Studies Pyrimidines - therapeutic use Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!